Synthetic Biology Firm Yinghang Bio Completes Hundred-Million-Dollar Series D Funding and Files IPO Prospectus

Leadsynbio Completes Hundreds of Millions in Series D FinancingRecently, synthetic biology company Leadsynbio completed its Series D financing round, raising hundreds of millions of RMB. Existing shareholders Lilly Asia Ventures and Sherpa Healthcare Partners continued to support the company. Following this round of financing, Leadsynbio will increase its investment in independent innovation and R&D, improve its industrial layout, strengthen team building, and comprehensively enhance its market and product competitiveness.

Leadsynbio, established in 2015, currently operates four core business segments: pharmaceuticals and health, animal nutrition, animal health, and crop protection. The company has built two R&D centers (in Suzhou and the United States) and two production bases (in Hunan and Anhui provinces). Its global R&D team has grown to 130 members, and its annual production capacity has reached the scale of tens of thousands of tons. Against the backdrop of China’s national carbon neutrality goals, Leadsynbio remains dedicated to technological innovation and applications in synthetic biology. Its products are characterized by mild production conditions, high raw material conversion rates, and environmental friendliness, thereby reducing wastewater discharge and carbon dioxide emissions during the manufacturing process.

Leadsynbio has grown into a national “Little Giant” enterprise specializing in specialized, refined, distinctive, and innovative products. In the face of severe global environmental challenges, synthetic biology and green bio-manufacturing technologies will play a pivotal role in the transformation and upgrading of traditional manufacturing industries. Leadsynbio is committed to bringing more environmentally friendly and economically viable products to the market, continuously creating value, and facilitating new transformations in the industrial manufacturing sector.